Company news

Share this article:
Amylin has announced a corporate restructuring that will result in a reduction of workforces by 25%, or 340 employees. “Sales revenues have not met the expectations we had when we scaled up our organization,” said Daniel Bradbury, president and CEO at Amylin, in a statement.
 
A Pfizer manufacturing plant in Indiana has been put up for sale. The plant most recently manufactured Exubera, an inhaled insulin therapy, which didn't catch on with patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION